MAP2K7 and acute myeloid leukemia: To answer this question, we established an in vitro model of MEK inhibitor resistance using THP-1 cells, incubated in increasing concentrations of selumetinib (clinical trial NCT00588809; completed), to identify the mechanism (s) that may lead to resistance in AML patients.